Introduction
Recent randomised active-controlled trials that included over 27,000 patients have established the direct oral anticoagulants (DOACs) as efficacious and safe treatment options for patients with acute symptomatic venous thromboembolism (VTE). [1] [2] [3] [4] [5] [6] With fixed dosing and no need for routine coagulation monitoring, the DOACs are convenient to administer and they are rapidly replacing vitamin K antagonists (VKA) for initial, long-term and extended VTE treatment.
Selection among the DOACs is challenging because they have not been compared in a head-to-head manner. Although the respective DOAC trials shared many similarities with regard to primary objective, comparator therapy, outcome definitions and central event adjudication, a number of differences existed in trial design and patient selection criteria. However, the impact of these trial differences on study outcomes is currently unknown. This gap in knowledge may have clinical consequences because indirect comparisons between DOACs have been conducted using meta-analytic or network meta-analytic techniques, [7] [8] [9] [10] [11] [12] but the results of these analyses may be misleading because of differences in study design and patient selection criteria. [13] [14] [15] This creates challenges for physicians and other health care professionals as they seek to understand, interpret, and apply the results of the studies in their clinical practices. [16, 17] To evaluate the impact of differences in trial design and inclusion and exclusion criteria on outcomes in DOAC VTE treatment trials we applied the main design features of the apixaban study (AMPLIFY) to patient cohorts from the studies with rivaroxaban (EINSTEIN DVT and EINSTEIN PE, which were performed as separate studies with a pre-specified pooled analysis) [1] [2] [3] 18 . In both study programs initial heparin therapy was not required for patients receiving DOAC treatment and many patients had no heparin or received only a single heparin dose prior to randomization.
More specifically, EINSTEIN DVT/PE and AMPLIFY shared the following features:
All three studies used the same blinded independent adjudication committee which employed identical diagnostic criteria for confirmation of the index and recurrent symptomatic VTE events and for the evaluation of suspected bleeding events. In all three studies, (a) recurrent VTE was evaluated for the intention-to-treat population, (b) bleeding events were evaluated for the on-treatment (+2 days) population, and (c)
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In EINSTEIN-DVT/PE, patients randomised to the rivaroxaban arm were given the drug at a dose of 15 mg twice-daily for 21 days and the dose was then reduced to 20 mg once-daily thereafter. In AMPLIFY, patients randomised to receive apixaban were
given the drug at a dose of 10 mg twice-daily for 7 days followed by 5 mg twice-daily thereafter. There was no downward adjustment of the doses of rivaroxaban or apixaban on the basis of clinical criteria such as older age, low body weight or moderate renal impairment. Heparin bridging was not given and the prerandomization use of heparin was restricted to a limited number of doses.
Comparator treatment in the trials consisted of enoxaparin (1 mg/kg body weight twice-daily) for a minimum of 5 days overlapping with a VKA (warfarin or acenocoumarol in EINSTEIN-DVT/PE and warfarin in AMPLIFY). Enoxaparin was stopped when the INR was 2 or higher and VKA was dose adjusted to maintain the INR between 2 and 3.
Patients were ineligible if they were allergic to the drugs used for comparator treatment, had limited life expectancy, had severe renal impairment, had bacterial endocarditis, used strong inhibitors of CYP3A4, or had received an investigational agent within the past 30 days prior to the first dose of study treatment. In addition, the studies excluded women who were pregnant or breast feeding and women of childbearing potential not taking adequate measures to prevent pregnancy.
On the other hand, EINSTEIN DVT/PE and AMPLIFY differed in a number design features.
The EINSTEIN-DVT/PE trials used a PROBE design (i.e., prospective, randomised, open, blinded endpoint evaluation), whereas the AMPLIFY trial was conducted in a double-blind, double-dummy manner and a point-of-care device was used to provide real or sham international normalised ratio (INR) values. The EINSTEIN-DVT/PE studies were conducted using a single protocol but applying separate randomization for patients with deep vein thrombosis (DVT) and for those with pulmonary embolism (PE) with or without accompanying DVT. In contrast, the AMPLIFY trial included patients with acute symptomatic VTE and stratified them according to presentation as DVT or PE. Taken together, the EINSTEIN-DVT/PE and AMPLIFY trials especially differed in the duration of therapy and in patient selection. In the EINSTEIN-DVT/PE trials, there were few exclusion criteria and anticoagulation therapy could be given for 3, 6 or 12 months at the discretion of the treating physician. [2, 3, 18] In contrast, the exclusion criteria were more stringent for the AMPLIFY study, and all patients were treated for 6 months. [1] To evaluate the impact of these trial design differences on treatment outcomes, we compared rates of recurrent VTE and major bleeding for EINSTEIN-DVT/PE patients
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who received at least 6 months of anticoagulant therapy in those who met or did not meet the eligibility criteria employed in the AMPLIFY trial.
Methods
Detailed descriptions of the study design of the EINSTEIN-DVT/PE and AMPLIFY trials have been published. [1] [2] [3] and were registered at ClinicalTrials.gov, numbers NCT00440193, NCT00439777, and NCT00643201.
Differences in study design of the EINSTEIN-DVT/PE and AMPLIFY trials
The steps taken to adjust the data from EINSTEIN-DVT/PE to mimic the AMPLIFY design are listed in Table 1 , which includes the number of patients involved. First, patients from EINSTEIN-DVT/PE with an intended treatment duration of 3 months
were excluded because such patients were not enrolled in AMPLIFY. Second, the evaluation was truncated at 6 months in EINSTEIN-DVT/PE patients whose intended treatment duration was 12 months. Third, the exclusion criteria used in AMPLIFY were applied to identify a similar cohort of patients enrolled in the EINSTEIN-DVT/PE trials (EINSTEIN cohort 1), and a cohort who would not have been eligible for AMPLIFY (EINSTEIN cohort 2). Separate analyses were performed for both cohorts.
Statistical Analyses

For comparison of demographic and clinical characteristics of patients in EINSTEIN-
DVT/PE cohort 1 and AMPLIFY, standardised difference scores were calculated. [19] For better comparison of outcome results, the EINSTEIN-DVT/PE results, which were originally expressed in hazard ratios, were presented as relative risk (RR). The 95% confidence intervals (CI) were calculated using the Mantel-Haenszel method and stratified according to the qualifying diagnosis (DVT or PE±DVT) and intended treatment duration (6 or 12 months). The times during which the INR was below, within or above the therapeutic range were calculated for each patient from the time of discontinuation of heparin until the end of treatment (including interruptions) and
were compared using multivariate ANOVA. Adverse events resulting in permanent discontinuation of study drug in the two EINSTEIN cohorts were compared using the chi-square test.
Outcome Measures
Efficacy and safety outcomes were defined identically in EINSTEIN-DVT/PE and AMPLIFY. The primary efficacy outcome was the adjudicated composite of recurrent symptomatic VTE (i.e. fatal or nonfatal PE and DVT). Major bleeding was defined as overt bleeding that was associated with a decrease in the hemoglobin level of 2 g/dL or more, required the transfusion of 2 or more units of blood, occurred in a critical site, or contributed to death.
Role of the funding source
Bayer HealthCare Pharmaceuticals and Janssen Research and Development, the funders of the EINSTEIN-DVT and EINSTEIN-PE studies, gathered, maintained, and extracted data. The authors had responsibility for interpreting the data and writing the article. JBW, AWAL, MPH, and JIW had access to the raw data. The corresponding author had full access to all of the data and the final responsibility to submit for publication.
Results
A total of 660 (8.0%) of the 8282 EINSTEIN-DVT/PE patients had an intended treatment of 3 months and were excluded from further analyses. Next, study duration was truncated at 6 months for 2681 patients who had a treatment duration > 6 months in EINSTEIN DVT/PE. As indicated in figure 1 , application of the AMPLIFY eligibility criteria to the 7621 EINSTEIN-DVT/PE patients with an intended treatment duration of 6 or 12 months resulted in 1) a cohort of 5253 EINSTEIN-DVT/PE patients whose inclusion criteria matched those of patients enrolled in AMPLIFY (EINSTEIN-DVT/PE cohort 1) and 2) a cohort of 2368 EINSTEIN-DVT/PE patients who would not been eligible for enrollment in AMPLIFY (EINSTEIN-DVT/PE cohort 2), Table 3 ).
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In EINSTEIN-DVT/PE cohort 1, the rate of recurrent VTE was significantly lower with rivaroxaban than with enoxaparin/VKA (1.5% and 2.3%, respectively; RR, 0.64; 95% CI, 0.43-0.95; p=0.027). In contrast, the rates of recurrent VTE with rivaroxaban and enoxaparin/VKA were similar in cohort 2 (2.6% and 2.3%, respectively; RR, 1.08; 95% CI, 0.65-1.79; p=0.77; Table 3 and Figure 2 ). Likewise, the rate of major bleeding was significantly lower with rivaroxaban than with enoxaparin/VKA in EINSTEIN-DVT/PE cohort 1 (0.8% and 1.7%, respectively; RR, 0.50; 95% CI, 0.30-0.82; p=0.0068) but not in cohort 2 (1.2% and 1.1%, respectively; RR, 1.03; 95% CI, 0.48-2.18; p=0.95; Figure 3 ).
The first recurrent VTE or major bleeding event in the intention-to-treat population occurred significantly less frequently with rivaroxaban than with enoxaparin/VKA in cohort 1 (2.4% and 4.0%, respectively; RR, 0.60; 95% CI, 0.44-0.81; p=0.0011) indicating a superior net clinical benefit with rivaroxaban. In contrast, the frequency of the first recurrent VTE or major bleeding event was similar with rivaroxaban and enoxaparin/VKA in cohort 2 (3.9% and 3.6%, respectively; RR, 1.06; 95% CI, 0.70-1.59; p=0.79). profile, since they more often had PE, prior VTE, known thrombophilia or active cancer, which has been shown to be a relevant risk factor for both VTE recurrence and bleeding during anticoagulation. [20, 21] . Therefore, our findings may even underestimate the impact of patient selection on outcomes in AMPLIFY.
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It may be argued that the majority of patients in EINSTEIN DVT/PE cohort 2 had provoked VTE, for which current guidelines recommend a treatment duration of 3 months, whereas these patients were selected to receive at least 6 months of anticoagulant therapy by their attending physicians. However, the risk of VTE recurrence after provoked VTE has been shown to range between 7-10% in the first two years after index event. [22, 23] . Furthermore, during anticoagulation we observed a numerically higher rate of recurrent VTE in patients with provoked VTE compared to those with unprovoked VTE, which likely reflects the co-morbidity profile of patients with provoked VTE chosen to continue anticoagulation beyond 3 months. In addition, in the benefit-risk evaluation of the EINSTEIN Extension study [24] , patients with provoked VTE had a similar recurrent VTE risk as compared to patients with unprovoked VTE. The number needed to treat with rivaroxaban to prevent 1 recurrent VTE was 16 for patients with unprovoked VTE and 14 for patients with provoked VTE, respectively. Finally, while VTE provoked by surgical triggers indeed has a very low risk of recurrence, VTE events provoked by "soft triggers" have been shown to have a considerably high VTE recurrence risk [25] that may, together with other factors such as family history, clot burden of index event, d-dimer values or patients` preferences, guide the decision to prolong anticoagulation beyond 3 months.
According to the outcome event rates of EINSTEIN cohort 2, the EINSTEIN-DVT/PE studies included a large proportion of patients who appear to have both a higher risk of recurrent VTE and a higher risk of major bleeding than those that met the inclusion and exclusion criteria used in AMPLIFY. Although the use of more stringent exclusion criteria may help to optimize internal validity, increase study feasibility, reduce cost, and alleviate ethical concerns by excluding patients who might be harmed by study participation, limiting enrollment may distort demographic characteristics (see Table   2 ) and yield lower rates of study outcomes (see Table 3 ). Therefore, the use of more stringent exclusion criteria has the potential to limit the generalizability (the so-called external validity) of the results to real-world practice. Consequently, enrollment of the broadest possible patient population is important to avoid such bias, [17] and the product label needs to reflect the applied exclusion criteria used in the various phase This study suggests that modest differences in study design can have a major impact on study outcomes. In the absence of head-to-head trials comparing one agent with another, this fact needs to be considered when making treatment decisions on the basis of cross study comparisons. Furthermore, our findings suggest that indirect comparisons such as network-analyses may be misleading, if they do not fully adjust for trial differences. Bacterial endocarditis Identical No correction -Prisoners/subjects who are involuntarily incarcerated -Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness -Any condition, which in the opinion of the investigator, would put the subject at an unacceptable risk from participating in the study Not specifically defined as exclusion criteria but these are general ineligibility criteria No correction A C C E P T E D M A N U S C R I P T
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